About
Introduction
Marcel van Straten (1974) studied Applied Physics at Delft University of Technology. His MSc project was on medical imaging
with MRI. His PhD project at the Academic Medical Center (now part of Amsterdam UMC) focused on the application of image
registration techniques in spiral CT. After that, he was a postdoctoral researcher at the Institute of Medical Physics of the
University of Erlangen-Nuremberg. He worked on the optimization and dosimetric aspects of CT. After joining Erasmus MC, he
has been granted certification as a medical physics expert.
with MRI. His PhD project at the Academic Medical Center (now part of Amsterdam UMC) focused on the application of image
registration techniques in spiral CT. After that, he was a postdoctoral researcher at the Institute of Medical Physics of the
University of Erlangen-Nuremberg. He worked on the optimization and dosimetric aspects of CT. After joining Erasmus MC, he
has been granted certification as a medical physics expert.
Field(s) of expertise
Current research interests include the optimization of CT image acquisition and an objective assessment of image quality.
Publications
https://www.ncbi.nlm.nih.gov/pubmed?term=(((van%20straten%20m%5BAuthor%5D%20AND%20(rotterdam%5BAffiliation%5D
%20OR%20amsterdam%5BAffiliation%5D%20OR%20erlangen%5BAffiliation%5D)))%20NOT%20%22One%20health%20(Am
sterdam%2C%20Netherlands)%22%5BJournal%5D)%20NOT%20(%22Behaviour%20research%20and%20therapy%22%5BJo
urnal%5D)
%20OR%20amsterdam%5BAffiliation%5D%20OR%20erlangen%5BAffiliation%5D)))%20NOT%20%22One%20health%20(Am
sterdam%2C%20Netherlands)%22%5BJournal%5D)%20NOT%20(%22Behaviour%20research%20and%20therapy%22%5BJo
urnal%5D)
Recent Findings
Previous studies in the lab have shown that autologous dendritic cells pulsed with allogenic tumor cell lysate was able to induce peripheral T cell activation and tumor-reactive T cell responses in patients with mesothelioma and pancreatic cancer. Current research focuses on how to initiate an effective immune response in the tumor as well as the tumor-draining lymph node using dendritic cell vaccination. Furthermore, we are studying novel approaches for (personalized) vaccination. In addition, we have identified T cell characteristics that underlie clinical efficacy of immune check inhibitors or chemotherapeutic agents in mesothelioma. The selected publications below give an impression of our work.
